RavenQuest Lists Warrants
VANCOUVER, British Columbia, June 29, 2018 (GLOBE NEWSWIRE) -- RavenQuest BioMed Inc. (CSE:RQB) (OTCQB:RVVQF) (Frankfurt:1IT) (“RavenQuest”) is pleased to announce that warrants issued pursuant to its February 28, 2018 brokered private placement (the “Warrants”) have been approved for listing by the Canadian Securities Exchange (the “CSE”). Each Warrant is exercisable for a two-year period from the date of issuance at a price of $1.50 per common share, subject to acceleration in the event that the closing price of the Company’s common shares on the CSE is greater than $2.75 for a period of ten consecutive trading days. The Warrants will commence trading on the CSE at the open of markets on July 3, 2018 under the ticker symbol RQB.WT.
About RavenQuest BioMed Inc.
RavenQuest is a diversified publicly traded cannabis company with divisions focused upon cannabis production, management services & consulting and specialized research & development. RavenQuest is a licensed producer with facilities located in Markham, Ontario and Edmonton, Alberta. RavenQuest maintains a research partnership with Montreal's McGill University focused upon cultivar (strain) recognition, plant stabilization and yield maximization of the cannabis plant.
The Company focuses on partnerships with Indigenous communities and has announced an MOU to construct a cannabis production facility on sovereign land of Fort McMurray First Nation #468. RavenQuest has also recently announced an LOI to acquire Western Agripharma Ltd., a late stage application with a production facility under construction on British Columbia's sunshine coast, a short ferry ride from Vancouver, BC.
On Behalf of the Board of Directors of
RAVENQUEST BIOMED INC.
"George Robinson"
Chief Executive Officer
| For further information, please contact: | Mathieu McDonald, Corporate Communications | |
| 604-484-1230 | ||
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.
© 2018 GlobeNewswire, Inc. All Rights Reserved.
Sanofi: First patient outside U.S. treated in global Kevzara (sarilumab) clinical trial program for patients with severe COVID-19
